DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DXCM executive vice president and chief financial officer Jereme M. Sylvain reported equity award activity in company common stock. On January 29, 2026, he acquired 7,123 shares at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023 after performance goals were achieved.
On the same date, 2,652 shares were withheld at $73.36 per share to satisfy tax obligations related to this vesting, which the footnotes clarify was not a sale. After these transactions, he directly beneficially owned 123,207 shares, including 83,328 unvested restricted stock units scheduled to vest between March 8, 2026 and March 8, 2028 and 79 shares acquired under the company’s employee stock purchase plan.
DexCom executive Michael Jon Brown, EVP and Chief Legal Officer, reported routine equity activity on January 29, 2026. He received 7,123 shares of common stock at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023 after performance goals were met.
To cover tax withholding on this PSU settlement, 2,653 shares were withheld by the issuer at $73.36 per share, which the filing states does not represent a sale by Brown. After these transactions, he directly owned 98,655 shares, including 86,490 unvested restricted stock units with various vesting schedules through March 8, 2028 and 83 shares acquired under the company’s employee stock purchase plan.
Dexcom Executive Chair Kevin R. Sayer reported equity compensation activity involving the company’s common stock. On January 29, 2026, he received 71,218 shares at $0 upon vesting of performance-based restricted stock units granted on March 9, 2023, after performance conditions were achieved.
On the same date, 34,257 shares at $73.36 were withheld by Dexcom to cover tax obligations related to this PSU settlement, which the filing states does not represent a sale by Sayer. Following these transactions, he directly beneficially owns 408,990 shares of Dexcom common stock.
Included in this amount are 138,091 unvested restricted stock units, consisting of 85,490 RSUs granted on March 8, 2025 that vest through March 8, 2028, 34,461 RSUs granted on March 8, 2024 that vest through March 8, 2027, and 18,140 RSUs granted on March 9, 2023 that vest through March 8, 2026.
Dexcom, Inc. filed a current report describing upcoming preliminary financial disclosures and business updates. President and CEO Jake Leach is scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, where he will discuss preliminary, unaudited results for the fourth quarter and full fiscal year 2025, as well as an initial financial outlook for fiscal 2026 and other information. These preliminary figures are subject to finalization in connection with Dexcom’s Form 10-K for the year ended December 31, 2025.
The report states that the presentation, together with two related press releases dated January 12, 2026 and January 7, 2026, includes forward-looking statements about revenue, margin guidance and strategic opportunities, which are subject to risks and uncertainties. The press releases are furnished as exhibits and are not deemed filed for liability purposes under the Exchange Act.
DexCom, Inc. director trade: A DexCom (DXCM) director reported selling 2,906 shares of common stock on 11/14/2025 at $59.05 per share. The transaction was executed by the Richard A. Collins Revocable Trust under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, designed to allow orderly sales over time. Following this sale, the trust holds 35,088 DexCom shares indirectly for the reporting person, and the director also holds 5,074 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of one year from grant or DexCom’s 2026 annual meeting of stockholders.
DexCom (DXCM) director Bridgette P. Heller reported an open-market sale of 1,012 common shares at $58.07 on November 12, 2025, executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
Following the transaction, she beneficially owns 27,031 shares directly, which include 5,046 unvested RSUs granted May 8, 2025 that vest on the earlier of the one-year anniversary or DexCom’s 2026 annual meeting.
DexCom (DXCM) reported insider purchases by its President & COO, Jacob Steven Leach. On 11/10/2025, he bought 15,700 shares at a weighted average price of $54.977 and 2,500 shares at a weighted average price of $55.4252, executed in multiple trades within disclosed price ranges.
Following these transactions, he directly beneficially owned 331,697 shares. That total includes 84,537 unvested restricted stock units scheduled to vest through March 2026–2028 as previously granted. In addition, 47,296 shares are indirectly held through the Gregg Family Grandchildren's Trust, for which his spouse serves as a trustee.
Dexcom (DXCM) insider activity: Director Richard A. Collins, through the Richard A. Collins Revocable Trust, sold 3,948 shares of common stock on 11/10/2025 at $55.17 per share, pursuant to a Rule 10b5-1 plan adopted on August 7, 2025.
Following the sale, 37,994 shares are beneficially owned indirectly by the Trust. In addition, 5,074 unvested RSUs granted on May 8, 2025 will vest on the earlier of the one-year grant anniversary or DexCom’s 2026 Annual Meeting of Stockholders.
Dexcom delivered strong Q3 2025 results, led by higher disposable sensor volumes. Revenue reached $1,209.3 million, up 22% year over year, with gross profit of $731.4 million and operating income of $242.5 million. Net income rose to $283.8 million, and diluted EPS was $0.70, compared to $0.34 a year ago.
Margins benefited from higher manufacturing volumes and lower legal expenses, partially offset by pricing headwinds and production inefficiencies. Other income improved on gains from equity investments. Operating cash flow was $659.9 million for the quarter, supporting a strong liquidity position; cash, cash equivalents and short‑term marketable securities totaled $3.32 billion at quarter end.
The company repurchased 2.4 million shares for $187.2 million under its $750 million authorization. U.S. revenue was $851.9 million (70% of total), with International at $357.4 million (30%). Dexcom noted a tax benefit from its Malaysia tax holiday. Convertible notes outstanding remained at $2.46 billion principal with low coupons, and no conversions were reported.
Dexcom, Inc. (DXCM) furnished an 8‑K to announce financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1.
The company stated that the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The submission also includes the Cover Page Interactive Data File (Inline XBRL).